Novartis continues earnings winning streak as it raises 2025 sales expectations

Ayisha Sharma

News Reporter

Novartis is starting the year on a strong note as several of its core medicines beat Wall Street’s sales projections, prompting the drugmaker to shift …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis continues earnings winning streak as it raises 2025 sales expectations

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

FDA approves Abeona’s skin disease cell therapy

Pfizer launches a new wave of cost cuts, expects $7.7B in total savings through 2027

With a new CEO, oligonucleotide biotech Creyon forges Eli Lilly partnership

Octagon Therapeutics shuts down after 'unresolved biology questions'

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

No­var­tis con­tin­ues earn­ings win­ning streak as it rais­es 2025 sales ex­pec­ta­tions

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Novartis continues earnings winning streak as it raises 2025 sales expectations